TEVA Teva Pharmaceutical Industries Limited Stock Quote

TEVA [NYSE]

Index	-	P/E	-	EPS (ttm)	-0.56	Insider Own	1.28%	Shs Outstand	1.11B	Perf Week	12.20%
Market Cap	8.91B	Forward P/E	3.17	EPS next Y	2.61	Insider Trans	-2.73%	Shs Float	1.10B	Perf Month	-18.66%
Income	-615.00M	PEG	-	EPS next Q	0.54	Inst Own	45.50%	Short Float	1.54%	Perf Quarter	-2.47%
Sales	15.56B	P/S	0.57	EPS this Y	110.30%	Inst Trans	0.11%	Short Ratio	1.84	Perf Half Y	-10.97%
Book/sh	8.44	P/B	0.98	EPS next Y	4.81%	ROA	-1.30%	Target Price	10.18	Perf Year	-21.59%
Cash/sh	2.02	P/C	4.10	EPS next 5Y	2.00%	ROE	-6.10%	52W Range	7.23 - 11.55	Perf YTD	3.37%
Dividend	-	P/FCF	15.24	EPS past 5Y	39.70%	ROI	4.50%	52W High	-28.13%	Beta	1.21
Dividend %	-	Quick Ratio	0.70	Sales past 5Y	-6.20%	Gross Margin	49.80%	52W Low	14.76%	ATR	0.38
Employees	37037	Current Ratio	1.10	Sales Q/Q	-8.10%	Oper. Margin	3.70%	RSI (14)	47.59	Volatility	3.99% 4.71%
Optionable	Yes	Debt/Eq	2.45	EPS Q/Q	-	Profit Margin	-4.00%	Rel Volume	0.57	Prev Close	8.28
Shortable	Yes	LT Debt/Eq	2.23	Earnings	May 03 BMO	Payout	-	Avg Volume	9.16M	Price	8.30
Recom	2.90	SMA20	-0.25%	SMA50	-4.74%	SMA200	-6.70%	Volume	4,882,846	Change	0.21%

May-17-22

Upgrade

BofA Securities

Underperform → Neutral

May-04-22

Downgrade

Piper Sandler

Neutral → Underweight

$11 → $7

Apr-05-22

Upgrade

Barclays

Equal Weight → Overweight

$11 → $13

Mar-25-22

Upgrade

Bernstein

Mkt Perform → Outperform

$11

Jan-27-22

Downgrade

Argus

Buy → Hold

Oct-28-21

Downgrade

Raymond James

Outperform → Mkt Perform

May-04-21

Downgrade

UBS

Buy → Neutral

$15 → $11

Apr-07-21

Resumed

RBC Capital Mkts

Sector Perform

$11

Nov-25-20

Initiated

Oppenheimer

Perform

Aug-06-20

Upgrade

Barclays

Underweight → Equal Weight

$10 → $13

Jul-27-20

Resumed

Goldman

Neutral

$12

Jun-01-20

Upgrade

SunTrust

Hold → Buy

Apr-24-20

Resumed

Citigroup

Neutral

$10

Apr-06-20

Upgrade

UBS

Neutral → Buy

$14 → $12

Feb-24-20

Downgrade

Edward Jones

Hold → Sell

Nov-12-19

Upgrade

JP Morgan

Underweight → Neutral

Oct-17-19

Upgrade

Gabelli & Co

Hold → Buy

Aug-07-19

Downgrade

Evercore ISI

Outperform → In-line

Jul-19-19

Initiated

Wolfe Research

Peer Perform

Jul-15-19

Downgrade

Morgan Stanley

Equal-Weight → Underweight

May-17-22 01:49PM	Teva Pharmaceutical Shares Real-World Data Of ProAir Digihaler In Asthma Patients Benzinga +6.19%
09:10AM	United Kingdom first to grant licence for Tevas ophthalmology biosimilar Ongavia (ranibizumab) Business Wire
08:00AM	Teva to Present Latest Research From Neurology Portfolio at the 2022 American Psychiatric Association Annual Meeting Business Wire
07:45AM	Teva Announces New Findings Highlighting Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder to Address Asthma Treatment Challenges Business Wire
May-12-22 08:00AM	Teva to Present Findings on Short-Acting Beta Agonist (SABA) Use in Asthma Patients and the Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder to Help Inform Treatment Decisions at American Thoracic Society 2022 Annual Meeting Business Wire
May-11-22 08:51AM	Teva, Allergan Ready To Pay $5B To Settle Lawsuits Related To Opioid Painkillers: Bloomberg Benzinga
May-10-22 03:10PM	Teva, Allergan Willing to Pay $5 Billion for Opioid Accord Bloomberg
08:00AM	Teva Publishes 2021 ESG Progress Report, Showcasing Further Integration of ESG Into Business, Robust Targets and Strengthened ESG Governance Structure Business Wire
May-06-22 10:30PM	Corcept Therapeutics (CORT) Q1 2022 Earnings Call Transcript Motley Fool
May-05-22 04:35PM	Teva's Q1 Results: Is the Stock About to Crash? Motley Fool -5.04%
May-04-22 11:07AM	TEVA Matches Q1 Earnings Estimates, Lowers 2022 Sales View Zacks
May-03-22 04:58PM	Teva CEO Sees a Final Opioid Settlement Coming This Year Barrons.com
04:07PM	Could Teva Join J&J, McKesson And Others In Settling Opioid Claims? Investor's Business Daily
11:00AM	Teva Pharmaceutical Industries (TEVA) Q1 2022 Earnings Call Transcript Motley Fool
10:36AM	Teva Posts Mixed Q1 Earnings, Cuts FY22 Sales Guidance Citing Copaxone Competition, Yet Shares Rise Benzinga
08:59AM	Tevas Earnings and Outlook Miss Estimates. Currency Moves Are to Blame. Barrons.com
07:42AM	UPDATE 3-Teva Pharm expects U.S. opioid case settlements to cost $2.6 bln Reuters
07:31AM	Teva shares slide 3% premarket as company swings to a loss and revenue falls MarketWatch
07:11AM	Teva Pharm expects U.S. opioid case settlements to cost $2.6 billion Reuters
07:00AM	Teva Reports First Quarter 2022 Financial Results Business Wire
May-02-22 03:55PM	Drug/Biotech Stocks Q1 Earnings Due on May 3: PFE, BIIB & More Zacks
08:00AM	Teva Announces Settlement with Lupin Resolving AUSTEDO® (deutetrabenazine) Patent Dispute Business Wire
Apr-28-22 05:21AM	3 No-Brainer Stocks to Buy With $200 During the Market Sell-Off Motley Fool
Apr-26-22 06:42PM	Walgreens, drugmakers blame others for San Francisco's opioid crisis Reuters
Apr-25-22 04:11PM	San Francisco To Start Opioid Epidemic Trial Against Teva, Walgreen: Reuters Benzinga
02:25PM	UPDATE 2-Walgreens, Teva accused of fueling opioid addiction in quest for new markets Reuters
09:00AM	Walgreens, Teva face San Francisco trial over opioid epidemic Reuters
Apr-21-22 09:05AM	Is Teva Pharmaceuticals a Brilliant Contrarian Pick? Motley Fool
Apr-20-22 11:14AM	Teva's (TEVA) Schizophrenia Drug Gets CRL From the FDA Zacks
06:17AM	Teva Pharmaceuticals Slides After Receiving FDA Complete Response Letter Investing.com
Apr-19-22 05:15PM	Teva and MedinCell Receive Complete Response Letter for TV-46000/mdc-IRM Business Wire
Apr-05-22 02:55PM	Trending Stocks on Tuesday: Top 10 Gainers Insider Monkey
12:03PM	Stock Market Lower As Benchmark Yield Jumps; This IBD 50 Stock Triggers Sell Signal Investor's Business Daily
07:34AM	Teva Canada Charts a New Prescription for Care CNW Group
Apr-04-22 04:05PM	Teva to Host Conference Call to Discuss First Quarter 2022 Financial Results at 8 a.m. ET on May 3, 2022 Business Wire +5.32%
10:55AM	UPDATE 2-West Virginia says J&J, drugmakers created 'tsunami' of opioid addiction Reuters
06:00AM	West Virginia faces off against J&J, drugmakers at trial over opioid epidemic Reuters
Apr-01-22 08:00AM	Teva to Present New Analyses of AJOVY® (fremanezumab-vfrm) Injection and AUSTEDO® (deutetrabenazine) Tablets at 2022 American Academy of Neurology Annual Meeting Business Wire
Mar-30-22 12:04PM	CVS to Pay $484 Million to Settle Opioid Case in Florida The Wall Street Journal +6.47%
11:26AM	Florida in $879 Million Opioid Settlement With CVS, Allergan and Teva Bloomberg
10:18AM	UPDATE 3-Florida reaches $878 million opioid settlements with CVS, Teva, others Reuters
09:38AM	Florida reaches $878 million opioid settlements with CVS, Teva, others Reuters
09:16AM	Florida reaches $878 mln opioid settlements with CVS, Teva, others Reuters
09:09AM	Teva Reaches Agreement With Florida to Settle the States Opioid-Related Claims Business Wire
Mar-26-22 07:31AM	Investing in Biopharma? Avoid These 2 Stocks Motley Fool
Mar-25-22 02:18PM	Teva stock jumps toward longest win streak in 2 years, after Bernstein analyst turns bullish MarketWatch +5.51%
04:10AM	Apple, Bed Bath & Beyond, Tilray Rise Premarket; Honest Company Slumps Investing.com
Mar-22-22 12:16PM	Is Teva Pharmaceutical Industries Limited's (NYSE:TEVA) 4.1% ROE Worse Than Average? Simply Wall St.
06:00AM	R.I. settles opioid claims against Teva and Allergan American City Business Journals
Mar-21-22 04:01PM	Rhode Island reaches $107 million opioid settlements with Teva and Allergan Reuters
03:36PM	UPDATE 3-Rhode Island reaches $107 mln opioid settlements with Teva and Allergan Reuters
02:55PM	Teva Reaches Agreement With Rhode Island to Settle Opioid-Related Claims Business Wire
Mar-17-22 02:19PM	35 Generic Drugmakers Sign To Manufacture Low-Cost Version Of Pfizer's COVID Pill Benzinga
Mar-14-22 06:00AM	Rhode Island takes Teva to trial in multibillion-dollar opioid case Reuters
Mar-11-22 11:09AM	AbbVie's (ABBV) Qulipta Meets Chronic Migraine Study Endpoints Zacks
Mar-07-22 08:00AM	Teva Announces Launch of a First Generic Version of Revlimid® (lenalidomide capsules), in the U.S. Business Wire
Mar-02-22 07:33AM	Teva Canada Welcomes Public Drug Plan Reimbursement by Alberta, Saskatchewan, Québec, Veteran Affairs Canada and the Non-Insured Health Benefits Program for Patients prescribed AJOVY® (fremanezumab) for the Preventive Treatment of Migraine in Adults CNW Group
Feb-28-22 06:06AM	Viatris to settle EpiPen antitrust litigation for $264 million Reuters
Feb-16-22 06:20PM	Top Stock Reports for Apple, Walt Disney & Broadcom Zacks
Feb-14-22 05:11PM	Buffetts Berkshire Takes Activision Blizzard Stake, Exits Teva Bloomberg
Feb-10-22 11:43AM	TEVA Stock Up on Q4 Earnings Beat, Sales Miss Estimates Zacks
03:00AM	COPAXONE® Label Now Indicates Its Use in Breastfeeding Mothers with Relapsing Multiple Sclerosis Business Wire
Feb-09-22 04:11PM	The Struggles Continue For Generic Drug Behemoth Teva Pharmaceutical Investor's Business Daily +8.44%
08:02AM	Drugmaker Teva may pay as much as $3.6 billion in U.S. opioid settlement Reuters
07:40AM	UPDATE 3-Drugmaker Teva may pay as much as $3.6 billion in U.S. opioid settlement Reuters
07:19AM	Teva stock falls after revenue falls below expectations, full-year profit outlook misses MarketWatch
Feb-08-22 03:22PM	Opioid crisis: 'You can't put the genie back in the bottle' with the damage done, Harvard professor explains Yahoo Finance Video
Feb-07-22 02:16PM	Teva, Texas Enter $225M Opioid Settlement Agreement Benzinga
10:35AM	UPDATE 2-Teva, Texas strike opioid settlement worth $225 million Reuters
10:12AM	Teva Reaches Agreement With Texas to Settle the States Opioid-Related Claims Business Wire
Feb-03-22 05:33PM	Hoka and Ugg Help Deckers Deliver Its Largest Quarter Ever Footwear News
Feb-01-22 08:00AM	Research Finds COVID Pandemic Worsened Health Equity Gap Business Wire
Jan-31-22 10:30AM	Are Warren Buffett's 3 Cheapest Stocks Screaming Buys? Motley Fool
Jan-24-22 09:30AM	2 Best Warren Buffett Value Stocks to Buy Right Now Motley Fool
Jan-20-22 09:06AM	10 Best Stocks to Buy Today According to Value Investor David Abrams Insider Monkey
Jan-19-22 05:36AM	3 Turnaround Stocks That Can Bounce Back Big Time in 2022 Motley Fool
Jan-18-22 04:24PM	Teva settles shareholder lawsuit over generic drug pricing for $420 million Reuters
04:22PM	UPDATE 2-Teva settles shareholder lawsuit over generic drug pricing for $420 mln Reuters
03:50PM	7 Stocks to Buy That Are Nowhere Near Being Overvalued InvestorPlace
08:00AM	Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2021 Financial Results and 2022 Financial Guidance at 8 a.m. ET on February 9, 2022 Business Wire
Jan-17-22 12:05PM	Teva Pharmaceutical Industries (NYSE:TEVA) earnings and shareholder returns have been trending downwards for the last five years, but the stock lifts 3.6% this past week Simply Wall St.
Jan-14-22 12:22PM	Hedge Funds Are Avoiding Teva Pharmaceutical Industries (TEVA) Insider Monkey
Jan-04-22 01:35PM	Teva to Present at the 40th Annual J.P. Morgan Healthcare Conference Business Wire
Jan-03-22 06:22AM	Teva Suffers Loss In New York's Opioid Trial Benzinga
05:06AM	22 Stocks That Could Double Your Money in 2022 Motley Fool
Dec-30-21 05:20PM	Teva Found Liable for Fueling Opioid Addiction in New York The Wall Street Journal -6.29%
04:38PM	Drugmaker Teva Pharmaceuticals found guilty for contribution to opioid crisis MarketWatch
01:44PM	Teva's stock swings to a sharp loss after jury finds its U.S. subsidiary violated rights of New Yorkers MarketWatch
01:29PM	Teva Statement Following New York Jury Ruling in Opioids Trial Business Wire
01:27PM	Teva, Units Held Liable for Fueling N.Y. Opioid Crisis Bloomberg
12:04PM	Drugmaker Teva fueled opioid addiction in New York, jury finds Reuters
12:00PM	UPDATE 3-Drugmaker Teva fueled opioid addiction in New York, jury finds Reuters
05:51AM	My Top 5 Portfolio Holdings for 2022 Motley Fool
04:52AM	Zacks Industry Outlook Highlights: Dr. Reddy's Laboratories, Teva Pharmaceutical and Amphastar Pharmaceuticals Zacks
Dec-29-21 09:21AM	3 Generic Drug Stocks to Watch Amid Stabilizing Pricing Pressure Zacks
07:50AM	1 Healthcare Stock to Avoid in 2022 Motley Fool
Dec-22-21 04:30PM	Teva Announces Launch of First-to-Market Generic Version of Narcan® (Naloxone Hydrochloride Nasal Spray), in the U.S. Business Wire
Dec-16-21 02:38PM	Forum Funds Buys Fiserv Inc, Tricon Residential Inc, CAE Inc GuruFocus.com
09:31AM	Teva Pharmaceutical Finance Netherlands IV BV -- Moody's affirms Teva's Ba2 ratings; outlook revised to stable Moody's
08:31AM	Legendary Value Investor Bill Millers Portfolio: Top 10 Stock Picks Insider Monkey

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system and pain area include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell S.A. to develop mdc-IRM, a risperidone extended-release injectable suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is based in Tel Aviv-Yafo, Israel.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Fridriksdottir Hafrun	Executive VP, Global R&D	May 17	Sale	8.22	130,000	1,068,067	1,387	May 19 07:31 AM
Dethlefs Sven	EVP, North America Commercial	Mar 07	Sale	7.37	6,993	51,515	165,381	Mar 08 04:04 PM
Daniell Richard	Exec. VP, European Commercial	Mar 07	Sale	7.37	22,576	166,311	43,182	Mar 08 04:03 PM
Drape Eric	Executive VP Global Operations	Mar 07	Sale	7.37	11,334	83,494	78,072	Mar 08 04:05 PM
Fridriksdottir Hafrun	Executive VP, Global R&D	Mar 07	Sale	7.37	8,941	65,866	126,087	Mar 08 04:07 PM
Stark David Matthew	Exec. VP Chief Legal Officer	Mar 07	Sale	7.37	9,057	66,720	61,137	Mar 08 04:13 PM
Stark David Matthew	Exec. VP Chief Legal Officer	Mar 04	Sale	7.48	23,254	173,998	42,311	Mar 08 04:13 PM
Fridriksdottir Hafrun	Executive VP, Global R&D	Mar 04	Sale	7.48	24,638	184,354	98,977	Mar 08 04:07 PM
Drape Eric	Executive VP Global Operations	Mar 04	Sale	7.48	23,458	175,524	61,191	Mar 08 04:05 PM
Daniell Richard	Exec. VP, European Commercial	Mar 04	Sale	7.48	36,376	272,183	20,280	Mar 08 04:03 PM
Dethlefs Sven	EVP, North America Commercial	Mar 04	Sale	7.48	3,904	29,212	147,422	Mar 08 04:04 PM
Stark David Matthew	Exec. VP Chief Legal Officer	Feb 28	Sale	8.14	6,452	52,533	21,380	Mar 02 07:54 AM
Shani Eli	EVP,Global Marketing&Portfolio	Feb 28	Sale	8.14	5,311	43,243	9,091	Mar 02 07:53 AM
Fridriksdottir Hafrun	Executive VP, Global R&D	Feb 28	Sale	8.14	7,590	61,799	65,509	Mar 02 07:47 AM
Drape Eric	Executive VP Global Operations	Feb 28	Sale	8.14	9,797	79,769	45,830	Mar 02 07:45 AM
Dethlefs Sven	EVP, North America Commercial	Feb 28	Sale	8.14	4,862	39,587	99,457	Mar 02 07:43 AM
Daniell Richard	Exec. VP, European Commercial	Feb 28	Sale	8.14	20,598	167,713	20,280	Mar 02 07:41 AM
Stark David Matthew	Exec. VP Chief Legal Officer	Feb 09	Sale	9.06	6,110	55,358	9,402	Feb 10 04:13 PM
Fridriksdottir Hafrun	Executive VP, Global R&D	Feb 09	Sale	9.06	6,116	55,412	51,417	Feb 10 04:09 PM
Drape Eric	Executive VP Global Operations	Feb 09	Sale	9.06	3,583	32,464	36,113	Feb 10 04:08 PM
Dethlefs Sven	EVP, North America Commercial	Feb 09	Sale	9.06	4,138	37,491	86,973	Feb 10 04:06 PM
Daniell Richard	Exec. VP, European Commercial	Feb 09	Sale	9.06	13,135	119,010	20,280	Feb 10 04:05 PM
Fridriksdottir Hafrun	Executive VP, Global R&D	Aug 10	Sale	9.95	50,860	506,021	41,412	Aug 12 04:04 PM
Drape Eric	Executive VP Global Operations	May 21	Sale	11.01	40,000	440,320	33,128	May 25 08:41 AM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience